NICE recommends aripiprazole for schizophrenia in young people

2011 011 Schizophrenia - aripiprazole

In final guidance published today, 26 January, NICE has recommended aripiprazole (Abilify, Bristol-Myers Squibb and Otsuka Pharmaceuticals) as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone.